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We read with interest the paper of Tarvasmäki et al.
[1] regarding the role of inotropes and vasopressors
in patients with cardiogenic shock. The authors
should be congratulated for their effort of prospect-
ively collecting a huge amount of data in one of the
most challenging settings. However, too much em-
phasis seems to be placed on the authors’ conclu-
sions, especially taking into account some of the
study’s limitations.
Right from the start of the paper, a fearsome asso-
ciation between adrenaline and short-term mortality
in the generic setting of cardiogenic shock is de-
scribed. However, up to 80 % of the patients enrolled
in the study had an acute coronary syndrome as the
cause leading to shock and this should have been
emphasized [2].
Adrenaline doses (maximum infusion rate 0.22 mcg/
kg/min (interquartile range 0.10–0.36)) were abnor-
mally high. It is well known that, depending on
vascular beds and concentration, adrenaline may in-
duce either vascular dilatation or contraction, with the
vasopressor effects arising at higher doses [3]. These
effects might be extremely amplified when coupled
with other vasopressors, leading to impaired organ
functions. In this study, patients receiving adrenaline
were also more likely to receive higher doses of nor-
adrenaline and dopamine.
Furthermore, patients receiving adrenaline were more
frequently resuscitated prior to admission, had a higher
incidence of low output state, and worse renal function
at admission. A more frequent recourse to a mechanical
assist device was also present in these patients. Consid-
ering the small sample size (40 patients received adren-
aline), might propensity score and multivariable analysis
take account of all these confounding and effect mo-
difiers? It is well known that researchers should use ex-
treme caution when interpreting the results of analyses
performed including a propensity score as a covariate
in a multivariable model [4].
Looking at the unadjusted odds ratios reported in
their Fig. 1 [1], we were impressed by the confidence
intervals. Levosimendan was used in 52 patients: this
sample is small but the effect estimation is accurate
because these patients were, presumably, clinically se-
lected. Noradrenaline was used in 162 patients: this
sample is larger but the effect estimation is less accur-
ate because, supposedly, these patients were a more
heterogeneous group. What about the patients receiv-
ing adrenaline? Were they at the extreme spectrum of
the population enrolled?
We believe there is not enough evidence to promote
a link between adrenaline administration and in-
creased death rates. Conversely, low to mid doses of
vasopressors might be considered part of an integrated
approach but only when massive myocardial damage
has not yet occurred.
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Authors’ response to “Vasopressors and inotropes in cardiogenic shock: is there room for ‘adrenaline
resuscitation’?”
Tuukka Tarvasmäki, Johan Lassus, Alexandre Mebazaa and Veli-Pekka Harjola
We thank Morici and colleagues for their interest in our
paper and acknowledging our work. They point out that
most patients in our study had cardiogenic shock (CS)
caused by acute coronary syndrome. This is clearly
stated in the results and also described in the previously
published paper on the characteristics and outcome of
this prospectively enrolled cohort of CS [5].
The dose of adrenaline and concomitant use of other
vasopressors and inotropes may indeed be subject to
variation according to local experience and practices. In
a contemporary randomized controlled trial in CS,
IABP-SHOCK II, the median dose of adrenaline was
0.3 μg/kg/min (Table S1 in the Supplementary Appendix
of [6]), which is very similar to the dose recorded in the
CardShock study. However, the association of adrenaline
with mortality was not dependent on the doses of other
vasopressors. The characteristics of patients treated
with and without adrenaline are also shown in Table 1
in our paper [1] and mortality analyses were adjusted
for differences. Mechanical assist devices other than an
intra-aortic balloon pump were used in very few pa-
tients overall.
We are aware of the limitations regarding propensity
score adjustment. Therefore, we performed additional pro-
pensity score matching as a sensitivity analysis, which con-
firmed the finding. In addition, further adjustment with
the use of intra-aortic balloon pump or other mechanical
assist devices did not change the results. While the study
population is of limited size and the estimates of treatment
effects may be susceptible to bias by unknown or unmeas-
ured variables, we think that the results are consistent. All
in all, while our study does not prove causality, it does
raise safety concerns about using adrenaline in CS.
Abbreviation
CS: Cardiogenic shock
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